Drug intelligence / Profile preview

Lactobacillus amylovorus

Development stage: Unknown
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus amylovorus is a species of lactic acid bacteria within the genus Lactobacillus, known for its ability to efficiently utilize starch and hydrolyze complex carbohydrates. It is Gram-positive, acid-resistant, and bile salt-resistant, with optimal growth at pH 5.5–6.0 but able to survive in more acidic environments[3]. This bacterium produces various enzymes such as α-galactosidase, β-galactosidase, α-glucosidase, β-glucosidase, and ferulic acid esterase[1][3]. As a probiotic candidate and food/feed additive, it has been studied for its antibacterial properties against pathogens like Salmonella typhimurium and Staphylococcus aureus[1][3]. In animal models (notably pigs), L. amylovorus can dominate the small intestine microbiota when provided with peptide-rich diets due to its preference for peptide-bound amino acids as nutrient sources[6]. Some strains have also been investigated as paraprobiotics for obesity prevention in humans[8].

Other names: L. amylovorus

Targets

PSII (Polysaccharide II antigen)

Beyond the preview

Go deeper on Lactobacillus amylovorus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus amylovorus.

Explore the full profile